Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
NCT03367741Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- May 2025
- Countries
- 2
01
Overview
A Phase 2 trial of cabozantinib in endometrial carcinoma, sponsored by National Cancer Institute. Started Apr 2018; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03367741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367741.